Novavax Inc

NVAX

Company Profile

  • Business description

    Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

  • Contact

    700 Quince Orchard Road
    GaithersburgMD20878
    USA

    T: +1 240 268-2000

    E: [email protected]

    https://www.novavax.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    1,992

Novavax Inc News & Analysis

stocks

Vaccine rollout and herd immunity to end the pandemic

Covid will create a $52bn vaccine and treatment market and usher in immunity by 2023, writes Morningstar's Karen Andersen.
markets

What a Covid-19 vaccine means for investors

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,633.1066.100.77%
CAC 407,182.9930.33-0.42%
DAX 4019,107.1039.07-0.20%
Dow JONES (US)43,870.35461.881.06%
FTSE 1008,191.2541.980.52%
HKSE19,229.97371.14-1.89%
NASDAQ18,972.426.280.03%
Nikkei 22538,283.85257.680.68%
NZX 50 Index13,041.90276.662.17%
S&P 5005,948.7131.600.53%
S&P/ASX 2008,393.8070.800.85%
SSE Composite Index3,267.19103.21-3.06%

Market Movers